DOTFM


2,5-Dimethoxy-4-trifluoromethylamphetamine is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It is the α-methylated analogue of 2C-TFM. The drug is the most potent DOx psychedelic.

Use and effects

According to Daniel Trachsel, DOTFM is active as a psychedelic in humans at doses of 0.3 to 1mg and its duration is not listed. It is the most potent psychedelic of the DOx family, followed by DOB.

Interactions

Pharmacology

Pharmacodynamics

DOTFM acts as an agonist at the serotonin 5-HT2A and 5-HT2C receptors. In drug discrimination tests in rats, DOTFM fully substituted for LSD and was slightly more potent than DOI. In addition, -DOTFM robustly induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, with equivalent potency as -DOI. The drug is around twice as potent as 2C-TFM in animal studies.
In contrast to -DOI, which has extraordinarily potent serotonin 5-HT2A receptor-mediated anti-inflammatory effects, DOTFM shows no anti-inflammatory effects. The differences between the drugs in this regard appear to be due to differences in functional selectivity at the serotonin 5-HT2A receptor.

History

DOTFM was first synthesized in 1994 by a team at Purdue University led by David E. Nichols. The threshold dose in humans was reported by Alexander Shulgin in his 2011 book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, who cited personal communication with an anonymous individual in 2003 as the source for the information. Subsequently, Daniel Trachsel described a wider dose range in 2013, although did not report its duration.

Society and culture

Legal status

Canada

DOTFM is a controlled substance in Canada under phenethylamine blanket-ban language.